Neurocrine Biosciences, Inc. (NBIX) Stock Forecast
NBIX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.59 / 5 from 29 analysts
- Price target
- $206.81 average of analyst targets
- Upside to target
- +52.4% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $1.98
- 52-week range
- $123.10 – $185.50
NBIX analyst ratings
29 analystsNumber of analysts at each rating.
NBIX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NBIX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.72 | $2.07 | $3.39 | $2.17 | +25.4% | 16 |
| Current fiscal year (2026) | $10.19 | $8.98 | $11.35 | $6.39 | +59.4% | 16 |
| Next fiscal year (2027) | $11.95 | $8.37 | $16.06 | $10.19 | +17.3% | 15 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NBIX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.05B | $1.02B | $1.10B | +31.5% | 23 |
| Current fiscal year (2026) | $3.90B | $3.84B | $4.07B | +36.4% | 25 |
| Next fiscal year (2027) | $4.56B | $4.27B | $5.00B | +16.9% | 23 |
NBIX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NBIX revenue: reported and forecast
NBIX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.67 | $2.72 | $2.72 | $2.73 | $2.72 | +1.9% | 1 up · 1 down |
| Current fiscal year (2026) | $10.20 | $10.19 | $10.20 | $10.21 | $10.19 | −0.1% | 1 up · 1 down |
| Next fiscal year (2027) | $12.68 | $11.95 | $11.97 | $11.88 | $11.95 | −5.8% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NBIX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NBIX beat in 7 of 12.
What analysts expect from NBIX
29 analysts cover Neurocrine Biosciences; their consensus rating is strong buy (4.59 on a 1–5 scale, where 5 is a strong buy). The average price target is $206.81, 52.4% above the latest close of $135.71. Analysts expect earnings of $10.19 per share for 2026, +59.4% from a year earlier. For 2027 the average estimate is $11.95 per share on revenue of $4.6 billion. Neurocrine Biosciences beat the EPS estimate in 7 of the last 12 quarters.
Related: NBIX income statement, NBIX key metrics, NBIX chart. See the NBIX stock overview for the latest quote and news.
NBIX forecast FAQ
What is Neurocrine Biosciences's price target?
The average analyst price target for Neurocrine Biosciences is $206.81, 52.4% above the latest close of $135.71.
Is Neurocrine Biosciences a buy, hold or sell?
Of 29 analysts covering Neurocrine Biosciences, 21 rate it a strong buy, 4 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Neurocrine Biosciences's EPS forecast?
Analysts forecast $10.19 per share for 2026 (range $8.98 to $11.35); for 2027 the estimate is $11.95.
What is Neurocrine Biosciences's revenue forecast?
The average revenue estimate for 2026 is $3.9 billion, growth of 36.4%; for 2027 it is $4.6 billion.
When does Neurocrine Biosciences report earnings?
Neurocrine Biosciences is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $1.98.
Does Neurocrine Biosciences usually beat earnings estimates?
Neurocrine Biosciences reported EPS at or above the analyst estimate in 7 of the last 12 quarters.